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Abstract  
Kappa-opioid receptor () antagonists are potential therapeutic agents for a range of 
psychiatric disorders. The feasibility of developing -antagonists has been limited by the 
pharmacodynamic properties of prototypic -selective antagonists, that is, they inhibit 
receptor signalling for weeks after a single administration. To address this issue, novel trans-
(3R,4R)-dimethyl-4-(3-hydroxyphenyl) piperidine derivatives, based on JDTic, were 
designed using soft-drug principles. The aim was to determine if the phenylpiperidine-based 
series of -antagonists was amenable to incorporation of a potentially metabolically labile 
group, whilst retaining good affinity and selectivity for the -receptor. Opioid receptor 
binding affinity and selectivity of three novel compounds (BU09057, BU09058 and 
BU09059) were tested. BU09059, which most closely resembles JDTic, had nanomolar 
affinity for the -receptor, with 15-fold and 616-fold selectivity over  and receptors, 
respectively. In isolated tissues, BU09059 was a potent and selective -antagonist (pA2 8.62) 
compared with BU09057 (pA2 6.87) and BU09058 (pA2 6.76) which were not -selective. In 
vivo, BU09059 (3 and 10 mg/kg) significantly blocked U50,488-induced antinociception and 
was as potent as, but shorter acting than, the prototypic selective -antagonist  norBNI. These 
data show that a new JDTic analogue, BU09059, retains high affinity and selectivity for the 
-receptor and has a shorter duration of -antagonist action in vivo.  
 
 
Keywords. kappa-opioid receptor, kappa antagonist, mu antagonist, norBNI, tail-withdrawal 
assay, CD-1 mouse  
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Introduction  
Kappa-opioid receptors () are Gi/o-coupled receptors that are activated by the neuropeptide 
dynorphin (1). Both prodynorphin, the precursor for dynorphin peptides, and -receptor 
expression is high in the brain structures underlying emotional control and stress responses, 
including brainstem nuclei, amygdala, hippocampus, and cortical regions (2-4). -agonists 
induce dysphoric responses in humans and aversive responses in rodents (5-7) whereas -
antagonists, -receptor gene deletion or prodynorphin gene disruption block stress-induced 
behavioural responses (8, 9). Hence there is growing interest in antagonists as potential 
therapeutic treatments for a variety of psychiatric diseases, including substance misuse and 
mood disorders (10, 11).  
 
High affinity, selectiveantagonists have an unusual pharmacodynamic property that is not 
well understood. A number of high affinity, selective, nonpeptidic antagonists have been 
identified, including (3R)-7-hydroxy-N-[(1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-
1-piperidinyl]methyl]-2-methylpropyl]-1,2,3,4-tetrahydro-3-isoquinoline-carboxamide 
(JDTic), 5’guanidinonaltrindole (GNTI) and norbinaltorphimine (norBNI) (12-14). However, 
these compounds all have very long-lasting effects in vivo. For example, a single dose of a 
selective antagonist, such as JDTic, has peak effects at 7 days and long-lasting receptor 
blockade up to 21 days post-injection (15). Diverse mechanisms have been proposed to account 
for this unusual long duration of action of selective antagonists (13). For example, it has been 
suggested that -antagonists are lipophilic and may form depots in the neuronal membranes 
which may lead to slow clearance of -antagonists from the brain. An alternative mechanism 
for the long-lasting action of antagonists is that they are resistant to metabolic pathways or 
produce metabolites that are active at the receptors, although little is known about the 
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metabolism of these compounds (13). More recently, -antagonists have been shown to produce 
ligand-directed signalling at the -receptor, with long-lasting -antagonists producing a c-Jun 
N terminal kinase (JNK) mediated inactivation of the -receptor (16, 17).Whatever the 
mechanisms are that account for the long-duration of -antagonist action, such 
pharmacodynamic properties may not be ideal for therapeutic development. Recently, a Phase 
1, first in human clinical trial with JDTic was terminated due to undisclosed adverse effects 
(ClinicalTrials.gov identifier NCT01431586). Therefore, there remains a need to develop 
alternative, including shorter-acting, selective -antagonists.  
 
Our approach has been to investigate whether the phenylpiperidine series of opioid antagonists 
can be modified to produce high affinity, selective -antagonists with a shorter duration of 
action than the prototypic -antagonists. We have synthesised ester containing ligands 
BU09057, BU09058 and BU09059 (Figure 1). The ligands in this study retained the trans-3,4-
dimethyl(3-hydroxyphenyl)piperidine moiety of JDTic, that serves as the message that 
recognises all opioid receptors and the  tetrahydroisoquinoline amino group that confers 
selectivity (address) for -receptors (18). The isopropyl side chain of JDTic has been omitted 
from two of the targets due to the synthetic challenge posed in incorporating it alongside the 
labile functionality.  The amide is replaced by the isosteric, and potentially metabolically labile, 
ester group in BU09057 and BU09058. BU09059 can be considered the closest analogue to 
JDTic, the side chain ester being used to mimic, as closely as possible, the isopropyl group 
present in JDTic.  It was not clear whether changes of this magnitude could be tolerated whilst 
retaining affinity and selectivity for the -receptor. This paper describes the in vitro and in vivo 
characterization of BU09057, BU09058 and BU09059.  
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Results and Discussion  
We have synthesized novel compounds with the aim of developing high affinity, 
selective -antagonists with a shorter duration of action than the prototypic -antagonists, such 
as norBNI. This is important for understanding the neurobiology of -receptors and also for the 
development of novel therapeutics that target -receptors. Novel ligands were designed using 
the structure of JDTic as a starting point (Figure 1). As far as possible, the critical SAR features 
identified by Thomas et al. (18, 19) to be essential for the high affinity and selectivity towards the 
-receptor were conserved. BU09057 and BU09058 both lack the isopropyl side chain found 
in JDTic, while in BU09059 an ester moiety is used to mimic the side chain. Potential sites of 
metabolism were designed within the chain connecting the message and address portions 
(BU09057, BU09058), or in a side chain off the connecting linker unit (BU09059). Like JDTic, 
each of the ligands has properties that would predict access to the brain and thus CNS activity 
(Figure 1). The synthesis and chemical characterization of the novel compounds is described in 
the Supporting Information. All compounds assayed were of ≥ 95% purity.  
 
The affinities of BU09057, BU09058, BU09059, norBNI and GNTI for the -, - and -opioid 
receptors were determined using the competitive [3H]-diprenorphine binding assay (Table 1). 
Of the novel compounds tested, BU09059 had highest affinity for the -receptor (Ki 1.72 ± 4.38 
nM) and showed promising selectivity for  (15 fold) in the range of the standard -opioid 
receptor antagonists norBNI and GNTI. Interestingly, the selectivity of BU09059 for  (616 
fold) far exceeded that of norBNI and GNTI. In this study, norBNI and GNTI appeared to have 
greater binding affinities for  and  receptors than previously published data, thereby reducing 
the apparent selectivity of norBNI compared to the 169-fold  selectivity reported by 
Takemori et al.(20), for example. Here, values were obtained using competitive [3H]-
diprenorphine binding, whereas others have used displacement of agonists such as [3H]-
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DAMGO, [3H]-DADLE and [3H]-ethylketocyclazocine (20) that may recognize different 
moieties  in the receptor-binding pocket and thus different displacement curves might be 
produced and give rise to somewhat different affinity values. Among all the ligands tested, 
BU09057 appeared to have the lowest affinity for both the -receptor (Ki 158.0 ± 20.6 nM) and 
the -receptor (Ki 186.0 ± 110.8 nM) and was not selective for and only weakly selective 
for BU09058 had the highest affinity for -receptors (Ki 6.55 ± 3.43 nM), rather than  
or receptors, and was weakly selective for  fold) but rather greater selectivity for  
(~37 fold). Interestingly, the novel test compounds showed lower affinity for the -receptor 
than the published reports for the parent compound JDTic(21) (Table 1). However, this change 
in binding affinity might be predicted since increasing the length of this side chain in JDTic has 
previously been shown to reduce both the binding affinity and selectivity for the -receptor(22). 
The novel compounds were without                                                                                                                             
agonist efficacy in the [35S]-GTPγS assay. At concentrations upto 10 µM, neither BU09057, 
BU09058 nor BU09059 produced stimulation of [35S]-GTPγS binding in C6- and CHO- cell 
membranes, indicating a lack of any agonist efficacy at  or receptors (n=3).  
 
Antagonist action and potency was confirmed in isolated tissue preparations (Figures 2, 3). 
Electrically-evoked twitches in the isolated guinea-pig ileum were inhibited by approximately 
90% by maximal concentrations of the -agonist U50488 and the -agonist DAMGO. 
BU09057 (150 nM) produced a significant rightward shift in the U50,488 concentration-
response curve (CRC) (control pEC50 = 7.63 (7.81 to 7.39, 95% CI); 150 nM BU09057 pEC50 
= 7.30 (7.34 to 7.25, 95% CI); n = 4; P < 0.01) and of the DAMGO CRC (control pEC50 = 
7.51(7.95 to 7.07, 95% CI); 150 nM BU09057 pEC50 = 6.85 (7.05 to 6.64, 95% CI); n = 4; P < 
0.05), without  significant effects on the U50,488 or DAMGO Emax (Figure 2). Similarly, 
BU09058 significantly antagonised the effects of both U50,488 (control pEC50 = 8.23 (8.62 to 
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7.84, 95% CI); 200 nM BU09058 pEC50 = 7.79 (7.82 to 7.75, 95% CI); n = 4; P < 0.05) and 
DAMGO (control pEC50 = 8.06 (8.38 to 7.74, 95% CI); 100 nM BU09058 pEC50 = 7.74 (7.93 
to 7.55, 95% CI); n = 4; P < 0.05) without affecting Emax (Figure 2). Thus, the - and -
antagonist effects produced were surmountable with increasing concentrations of agonist.  
Antagonist potencies (pA2) were determined by Schild plot analysis, in each case unity was 
within the 95% confidence limits of the slope of the Schild plot (Table 2). These experiments 
demonstrated that BU09057 and BU09058 are moderately potent antagonists at both the - and 
-receptors with no selectivity for either subtype.  
 
In contrast, BU09059 was revealed to be a potent and selective -antagonist in the isolated 
guinea-pig ileum. Increasing concentrations of BU09059 produced reversible progressive 
parallel rightward shifts of the U50,488 CRC (control pEC50 = 7.80 (8.50 to 7.09, 95% CI); 20 
nM BU09057 pEC50 = 6.98 (7.13 to 6.83, 95% CI); n = 4; P < 0.05), without affecting Emax 
(Figure 2). Interestingly, BU09059 had no significant effects on the DAMGO CRC at 
concentrations up to 100nM. The pA2 value for BU09059 at the -receptor was 8.62 (Table2). 
To further investigate the selectivity of BU09059 for -receptors, the mouse vas deferens assay 
was used to examine effects at - and -receptors (Figure 3). Electrically-evoked twitches of 
the mouse vas deferens were inhibited by almost 90% by maximal concentrations of the -
agonist DAMGO and the -agonist DPDPE. At concentrations up to 5 M, BU09059 was 
without significant effect on the DAMGO CRC (control pEC50 = 7.12 (7.22 to 6.98; 95% CI); 
5 M BU09059 pEC50 = 7.09 (7.36 to 6.83; 95% CI); n = 4; P>0.05)  or the DPDPE CRC 
(control pEC50 = 8.92 (9.06 to 8.77; 95% CI); 5 M BU09059 pEC50 = 8.66 (8.89 to 8.44; 95% 
CI); n = 4; P> 0.05).  There was no significant effect of BU09059 on Emax values for both 
DAMGO and DPDPE. Thus, BU09059 possessed negligible antagonist actions at - and -
receptors.  
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BU09059 was considered the closest analogue to JDTic, the ester side chain being slightly 
larger and electronically dissimilar to the isopropyl group of JDTic. Previously, a JDTic 
analogue with slightly increased bulk at this position has been reported to retain high affinity 
and selectivity for the -receptor (14, 23) suggesting that introduction of the ester moiety in 
BU09059 might be well tolerated. Indeed, BU09059 demonstrated the highest affinity (Ki 1.72 
nM), selectivity ( 15-fold;  616-fold) and antagonist potency (pA2 8.62) for the -
receptor among the novel phenylpiperidine-derived ligands tested. Furthermore, there were no 
detectable - or -receptor antagonist effects of BU09059 in isolated tissue preparations at 
concentrations up to 5 μM. Thus, introduction of the ester group appeared to cause only a 
modest disruption of the binding affinity for the -receptor in comparison to JDTic (Ki 0.41 nM 
in cloned human CHO-k cells)(21). This change in binding affinity was expected, since Cueva 
et al. (24) have shown that increasing the length of this side chain in JDTic (from an isopropyl 
to a sec-butyl group) reduces both the antagonist potency and selectivity  for the -receptor by 
13-fold (versus the -receptor) in the agonist stimulated [35S]-GTPS binding assay. In addition, 
BU09059 appeared to be more selective in the functional assays than the binding assays and 
this mirrors the findings for JDTic, which had only 12-fold selectivity in binding assays but 
substantially greater selectivity in functional assays (discussed in (21)). Overall, BU09059 
demonstrated a highly selective -receptor profile that made it particularly interesting for 
further testing in vivo. 
 
Of the phenylpiperidine ligands tested, BU09057 was shown to have the lowest affinity for both 
the -receptor (Ki 158.6 nM) and the -receptor (Ki 475.0 nM) in the [3H]-diprenorphine 
binding assay. In the isolated guinea pig ileum, BU09057 appeared to demonstrate modest 
antagonist potency for both the - (pA2 6.87) and -receptor (pA2 7.01) indicating it was a non-
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selective mixed  antagonist. The substitution of the original amide containing chain in 
JDTic, with an ester in BU09057, coupled with loss of the isopropyl side chain, appeared to 
dramatically reduce the affinity for the -receptor (almost 100 fold compared with BU09059). 
Its closest analogue, BU09058 contained a one carbon longer ester linker and, among the novel 
compounds, BU09058 had the highest affinity for the -receptor (Ki 6.55 nM) and the -
receptor (Ki 221.0 nM), with a somewhat reduced affinity for the -receptor (Ki 25.2 nM). 
However, in the isolated guinea pig ileum, BU09058 had a very similar antagonist profile to 
that of BU09057 with modest antagonist potency at both the - (pA2 6.76) and -receptors (pA2 
7.03). The major effect of the structural differences between BU09057 and BU09058 compared 
with BU09059 was loss of selectivity for the -receptor. The profile displayed by BU09057 
and BU09058 may in itself prove interesting as mixed receptor antagonists have recently 
been shown to have anxiolytic- and or antidepressant-like activity in preclinical studies (25). In 
addition, a combination of buprenorphine, a partial  agonist and  antagonist, and a selective 
 antagonist (ALKS33BUP), together providing predominantly  and  antagonism, has 
completed Phase II clinical trials in major depressive disorder patients (ClinicalTrials.gov 
identifier NCT1381107). 
 
For in vivo studies, we first established that intraperitoneal injection in adult CD-1 mice of 1, 
3.2 and 10 mg/kg of BU09057, BU09058 and BU09059 did not produce any adverse behaviours 
over a 48h observation period (n=3, per dose per drug).  The ability of these novel 
phenylpiperidine derivatives to block -receptors in vivo was then examined using the blockade 
of U50,488-induced antinociception in the warm water tail-withdrawal assay in CD-1 mice 
(Figure 4). Tail-withdrawal responses were measured at 1 h, 24h, 7 d, 14 d and 21 d after a 
single injection of test ligand (3 mg/kg or 10 mg/kg).  A 2-way repeated measures mixed model 
analysis revealed a significant main effect of drug treatment (F(8, 63) = 20.76, p < 0.001) and 
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time (F(4, 252) = 20.62, p < 0.001). The interaction between treatment and time was also 
significant (F(32, 252) = 4.83, p < 0.001). 
 
Within-treatment post hoc pairwise comparisons revealed that at 24 h post-injection, BU09057, 
BU09058, and BU09059 (3 and 10 mg/kg) significantly blocked U50,488-induced 
antinociception compared to saline (all p <0.05), demonstrating functional -antagonist activity 
in vivo (Figure 4). However, BU09059 (3 mg/kg), displayed significantly greater blockade of 
U50,488 actions than did norBNI (3 mg/kg, p < 0.05) suggesting that it is more potent or has a 
more rapid onset of action than norBNI. BU09059 (3 and 10 mg/kg) significantly blocked 
U50,488-induced antinociception after 1 h post-injection, maintaining maximal peak until 24 h 
(compared to saline-controls, p < 0.05). At 7 and 14 d post-injection, norBNI continued to 
produce significant blockade of U50,488-induced antinociception (p<0.05, compared to saline) 
consistent with its reported long duration of action in vivo (15). However, BU09059 (3 and 10 
mg/kg) showed significantly diminished antagonist activity, compared to norBNI (at equivalent 
doses, all p < 0.05) at 7 and 14 days post-injection. Overall, these results show a different 
timecourse of effect for the novel phenylpiperidine derivatives compared to norBNI, with 
BU09059 particularly showing a more rapid onset of action and a more rapid reversal of effects 
suggesting that this compound has a shorter duration of action than norBNI. 
 
In vivo BU09059 was equipotent to the prototypic -antagonist norBNI but exhibited a different 
pharmacodynamic profile. Blockade of U50,488-induced antinociception in the tail- 
withdrawal assay by a single injection of norBNI, was effective 1 h post-injection, peaked at 7-
14 d and was significantly diminished by 21 d post-injection, consistent with previous reports 
in the literature  (15, 26). BU09059 had a similar rapid onset of blockade of U50,488-induced 
antinociception, effective 1h post-injection. However, in contrast to norBNI, peak effects of 
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BU09059 were observed at 24h post-injection and significantly reduced by 7 days. On the other 
hand, both BU09057 and BU09058 seemed to produce long-lasting -antagonism at days 7-14. 
These two compounds are the more distant analogues of JDTic, lacking the isopropyl side chain 
entirely. The modification in BU09059, where the isopropyl side chain is replaced with an ester, 
indicates that this connecting linker unit may be structurally important in determining the 
duration of action of -antagonists, as well as influencing -selectivity. 
 
These data suggest that the insertion of the hypothetically metabolically labile ester side chain 
into BU09059 can reduce the duration of -antagonist action while maintaining high affinity 
and selectivity for the -receptor. This approach to achieving shorter-acting compounds by 
integrating hydrolysable ester groups has been successful in a wide range of target drugs, 
including the receptor analgesic remifentanil (27), beta-blockers (28, 29), anticholinergics (30) 
and antiarrhythmic agents (31). The prolonged -receptor antagonist activity of high affinity, 
selective -antagonists such as JDTic has been seen as a limitation towards successful drug 
development for a number of therapeutic indications. A Phase 1, first in human clinical trial 
with JDTic was indeed terminated in 2012 due to undisclosed adverse effects 
(ClinicalTrials.gov identifier NCT01431586). Therefore, there is a need to develop alternatives, 
including shorter-acting, selective -antagonists.  
 
Several new -antagonists have recently been reported with a shorter duration of -antagonist 
activity (32-36). Different approaches have been adopted in the development of these ligands 
with some appearing to be shorter acting because they do not produce prolonged inactivation 
of the -receptor via JNK activation (17). It is not known to what extent a different metabolic 
profile contributes to their shorter duration of action. Until recently, very little was known 
about the metabolism of the long-acting selective -antagonists in mice. JDTic, norBNI and 
 12
GNTI all bind reversibly to -receptors in vitro and do not form covalent bonds with the 
receptor. Thus, in vitro they are competitive antagonists producing surmountable antagonism, 
although in vivo they are pseudoirreversible antagonists (12). Following intraperitoneal 
administration, JDTic, norBNI and GNTI (all 10 mg/kg) are rapidly absorbed and eliminated 
from the plasma (37). Clearly, plasma concentrations do not parallel the slow onset and long 
duration of -antagonism seen in vivo. These authors argue that their findings support the 
idea that selective -antagonists, with long duration of activity, act to produce an irreversible 
change in the -receptor, such as JNK-mediated inactivation. However, these authors also 
demonstrated that JDTic was only slowly eliminated from the brain, possibly because of 
accumulation in lysosomes, and that this effect might contribute to its long duration of action. 
Munro et al.(37) also demonstrated that JDTic, norBNI and GNTI were hydrophilic with a low 
affinity for brain homogenate suggesting that they were unlikely to form lipid depots or 
nonspecific tissue binding. More recently, norBNI has also been shown to be detectable in 
mouse brain homogenates isolated up to 21 days after intraperitoneal administration (10 
mg/kg), which outlasted its apparent -antagonist activity in the tail-withdrawal assay (38). 
However, the levels of norBNI detected were proven to be below the threshold required to 
produce -antagonism, supporting the idea that the long duration of -antagonist action 
cannot be simply explained by the presence of antagonist in the brain and corresponding 
occupancy of  receptors. BU09059 has a shorter duration of action in vivo than norBNI, 
JDTic and GNTI. While esters are a potential metabolic hotspot in a molecule, they are not 
necessarily easily metabolised, with some being metabolically stable. Furthermore, BU09059 
lacks the isopropyl group present in JDTic and this may contribute to the shorter duration. 
Further determination of the pharmacokinetics of BU09059 in mouse brain and its potential 
metabolic products may provide insights regarding the shorter duration of activity of this 
novel compound. With its shorter duration of action, high selectivity and potent -antagonist 
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action in vivo, BU09059 will be a useful novel tool in understanding the functional role of -
receptors and the chemistry of -receptor-drug interactions.  
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Methods  
Materials. Cell culture reagents were from Gibco Life Sciences (Grand Island, NY). All other 
chemicals were analytical grade and purchased from Sigma-Aldrich except: guanosine-5’-O-
(3-[35S]-thio)triphosphate ([35S]-GTPγS) and [3H]-diprenorphine (Perkin Elmer, MA, USA), 
DAMGO and DPDPE from Abcam Biochemicals. Norbinaltorphimine dihydrochloride 
(norBNI), 5’-guanidinonaltrindole trifluoroacetic acid (GNTI), BU09057, BU09058 and 
BU09059 were synthesised (Figure 1) (>95% purity) in the Department of Pharmacy and 
Pharmacology, University of Bath.  
 
Synthesis and chemical characterization of BU09057, BU09058 and BU09059. The 
compounds were prepared from (+)-(3R,4R)-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine (purchased from Astatech Inc and used as received) as described within the Supporting Information. 7-Hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid was purchased from Acros Organics and other reagents and solvents were from Sigma Aldrich. NMR spectra were obtained on a JEOL Delta-270MHz instrument with TMS as internal standard. ESIMS, microTOF (Bruker). Ligands were tested as their hydrochloride salts, formed by adding 5N HCl in isopropanol to an ether solution of the compound until just acidic. 
 
Animals. Experiments were performed in accordance with UK Home Office guidelines and the 
Animals (Scientific Procedures) Act 1986. Adult (8-9 weeks, 27-38 g) male CD-1 mice, from 
Charles River (Crl: CD1(ICR)) and bred at the University of Bath, were housed in groups of 3-
4 in cages provided with a shelf, wood shavings and nesting material. The colony rooms were 
held under a 12 h light/ dark cycle (lights on at 07:00), at 20 ± 2°C with ad libitum food and 
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water. Adult, female, Dunkin Hartley guinea-pigs (300–350 g, Harlan UK) were housed in open 
floor pens at 19 ± 2°C, on 12 h light/dark cycle with ad libitum food and water.  
 
Cell membrane preparation.   Cell membranes were prepared from C6 rat glioma cells 
stably transfected with the rat -receptor (C6-;) or receptor (C6-;  and CHO cells stably 
expressing the human -receptor (CHO-(39-41). 
 
[3H]-Diprenorphrine competitive binding assay.  Membranes (20 g) were incubated in 50 
mM Tris-HCl, pH 7.4 with a saturating concentration of [3H]-diprenorphine (0.2–0.3 nM) in 
the absence or presence of test compounds (norBNI, GNTI, BU09057, BU09058, BU09059) 
with a concentration range of  0.1 pM to 1 M, for 1 h, in a shaking water bath at 25°C. 
Nonspecific binding was measured using 50 µM naloxone. Samples were filtered through 
GF/C glass-fibre filtermats mounted on a Brandel cell harvester and rinsed with 4°C 50 mM 
Tris-HCl, pH 7.4 buffer. Filtermats were dried and radioactivity in each sample area was 
counted. Three triplicate determinations were carried out for all compounds at each opioid 
receptor. Data were analysed using Prism 5.0 (GraphPad Software, CA, USA) to determine Ki 
values from the IC50 values using the Cheng-Prusoff equation.  
 
[35S]-GTPγS assay.  As described previously (42), C6-µ/δ or CHO-k membranes (20 µg) were 
incubated in 20 mM Tris-HCl, pH 7.4 buffer containing (mM) 5 MgCl2, 100 NaCl, 2.2 
dithiothreitol, 30 µM GDP, 0.1 nM [35S]-GTPγS, and 1pM to 10M test compound 
(BU09057, BU09058, BU09059), 10 µM U69,593 or 10 µM DAMGO or Super Q H2O. The 
membranes were incubated for 60 min in a shaking water bath at 25°C. Samples were filtered 
through GF/C glass-fibre filtermats and then processed as described above. [35S]-GTPγS 
stimulation by test compounds was expressed as a percentage of the stimulation by 10 µM 
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U69,593 or DAMGO for the - and -receptor, respectively. The -receptor agonist activity 
of the novel compounds was not evaluated because of the very low affinity of the compounds 
for the -receptor compared to the - and -receptors. Data were analysed using Prism 5.0 
(GraphPad Software, CA, USA). 
 
Isolated tissue preparations. Guinea pigs were killed by CO2 euthanasia. Approximately 3 cm 
of ileum was mounted, under 1g tension, in a 35 ml organ bath at 37°C containing gassed 
(95%O2 / 5%CO2) Krebs solution (mM): 118 NaCl, 11.6 glucose, 25 NaHCO3, 4.7 KCl, 1.2 
KH2PO4, 1.2 CaCl2.6H2O, 1.2 MgSO4.7H2O. Electrical field stimulation (100 V, 1 ms pulse 
duration, 0.033 Hz) via platinum wire electrodes (Grass S-D9 stimulator), was applied for 40 
min prior to drug addition. Twitch contractions were recorded using an isotonic transducer 
connected to Powerlab/200 and Chart software (AD Instruments).  
 
The vas deferens was isolated from CD-1 mice, killed by CO2 euthanasia. Tissues were 
mounted, under 0.5g of tension via an isometric transducer, in a 5 ml organ bath containing 
gassed (95%O2 / 5%CO2) Mg2+-free Krebs solution at 37°C. A grass S-88 electrostimulator 
was used to deliver a 25 ms train of pulses (3 pulses, 10 ms apart, 1 ms duration) at a frequency 
of 0.05 Hz. Twitches were recorded using a Powerlab 4/26 and Chart software (AD 
Instruments). 
 
Cumulative concentration response curves (CRCs) were constructed for the -agonist U50-488 
(1nM-1M) or the -agonist DAMGO (0.1 nM –1 M) or the -agonist DPDPE (0.1nM-
0.1M), in the absence and presence of increasing concentrations of test ligands; BU09057, 
BU09058 and BU09059. Following each CRC, tissues were washed until twitch amplitudes 
returned to baseline. Agonist CRCs were repeated after incubation with antagonist for 30 min. 
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An individual tissue was only exposed to one antagonist to avoid potential carryover effects. 
Agonist responses were calculated as percentage maximal response: (average baseline twitch - 
average agonist response twitch)/(average baseline twitch - average maximum agonist 
inhibition of twitch) x 100. Agonist potency was determined as the negative logarithm of the 
concentration required to produce 50% of the maximum response (pEC50).  Shifts of the agonist 
concentration-response curve by the presence of a competing ligand (agonist pEC50 values, 
Emax values)  were compared by a one-way ANOVA followed by Dunnett’s post hoc test. 
Probability p < 0.05 was taken to be statistically signiﬁcant.  The concentration ratio for the 
rightward shift of the agonist curve in the presence of antagonist was used to calculate the pA2 
from a Schild linear regression plot (43). Values are reported as mean ± SEM or mean ± 95% 
confidence interval (CI) for each treatment group. 
 
 
Establishing non-toxic doses in vivo. Drugs were dissolved in 0.9% w/v saline solution and 
administered via intraperitoneal injection at volumes of 10 mL/kg. Toxicity of BU09057, 
BU09058 and BU09059 was assessed in naïve mice using a step-wise minimal numbers 
approach, starting at a low dose (1 mg/kg) and monitoring of behaviours (including respiration 
rate, posture, locomotor behaviour, pilo erection) (44). If no toxicity was seen, higher doses up 
to 10 mg/kg were administered in step-wise increments. 
 
Warm water tail-withdrawal test. In vivo studies commenced at 10:00 am. Mice were 
positioned vertically and ~2 cm of the tail placed into a beaker of warm water (50oC). The 
control tail-withdrawal latency was measured 30 min after saline injection (45). Subsequently, 
the agonist U50,488 (10 mg/kg) was administered and the test latency measured 30 min later. 
A cut-off time of 15 s was used to prevent tissue damage. Antinociception was calculated as 
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percent maximum possible effect (% MPE) = (test latency - control latency) / (15 s - control 
latency) x 100. Mice were pre-treated with 0.9 % w/v saline, norBNI, BU09057, BU09058 and 
BU09059 (3 and 10 mg/kg) to assess their ability to block U50,488 induced antinociception in 
the tail-withdrawal test at 1h, 24 h, 7, 14 and 21 days post-injection. Data were analyzed using 
a 2-way repeated measures mixed model approach, with treatment factor “Treatment” and 
repeated factor “Time” using InVivoStat software (46). Planned pairwise comparisons were 
made and Bonferroni’s correction for multiple comparisons applied. Values are reported as 
mean ± SEM or mean ± 95% confidence interval (CI) for each treatment group. 
 
Supporting Information Available: The details of synthesis and chemical characterization of 
the novel compounds is included. This material is available freeof charge via the Internet at 
http://pubs.acs.org 
 
 
Abbreviations: ANOVA, analysis of variance; CRCs, concentration response curves; , delta 
opioid receptor; GNTI, 5’guanidinonaltrindole;  JDTic, (3R)-7-Hydroxy-N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpro pyl)-1,2,3,4-tetrahydro-3-isoquinoline carboxamide; JNK, c-Jun N terminal kinase; norBNI, norbinaltorphimine;  , kappa 
opioid receptor; , mu opioid receptor; % MPE, percent maximum possible effect; U50,488, 
(trans)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)-cyclohexyl]benzeneacetamide 
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Table 1. Summary of antagonist affinity and selectivity for -, - and -receptors in the 
competitive [3H]-diprenorphine binding assay.  
 
Ligand Ki (nM) -selectivity 
    
JDTica 0.41 ± 0.10 0.96 ± 0.0 29.6 ± 11.9 2 72 
NorBNI 0.29 ± 0.02 1.99 ± 2.38 0.46 ± 0.09 14 2 
GNTI 0.37 ± 0.16 4.74 ± 1.96 2.86 ± 1.45 13 8 
BU09057 158.6 ± 20.6 186.0 ± 110.8 475.0 ± 175.0 1 3 
BU09058 25.2 ± 8.2 6.55 ± 3.43 221.0 ± 137.0 <1 9 
BU09059 1.72 ± 4.38 26.5 ± 8.4 1060.0 ± 320.0 15 616 
 
Ki values were determined by competitive displacement of [3H]-diprenorphine (0.2 nmol·L-1) 
binding in CHO-, C6- and C6-cell membranes. Values are the mean ± SEM of n=3 in 
triplicate experiments. a Values previously reported and obtained using cloned human opioid receptors transfected into CHO cells(21).                                          
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Table 2. Summary of antagonist potency at - and -receptors in the isolated guinea-pig 
ileum preparation 
 
Ligand Antagonist potency (pA2) 
 
BU09057 6.87 (7.13-6.35) 
(134.9 nM) 
7.01 (7.89-6.79) 
(97.7 nM) 
BU09058 6.76 (7.45-6.05) 
(173.8 nM) 
7.03 (7.32-6.90) 
(93 nM) 
BU09059 8.62 (9.12-8.03) 
(2.39 nM) 
- 
NorBNI 8.30 (10.3-7.72) 
(5.0 nM) 
- 
 
pA2 values were determined by Schild plot analysis. Values are the mean and 95% confidence 
interval for n=4 tissues. Values for the prototypic -antagonist norBNI were obtained from our 
previously published data (25). Mean values are also shown as nM. 
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FIGURE LEGENDS 
 
Figure 1 Structures of BU09057, BU09058 and BU09059 alongside JDTic and predicted  
physicochemical properties (ACD/I-Lab-2, accessed via the Royal Society of Chemistry 
National Chemical Database Service) TPSA: topological polar surface area. 
 
Figure 2. Cumulative concentration-response curves, in the guinea-pig ileum for U50,488 and 
DAMGO (maximal agonist concentrations 1 M), in the presence of increasing concentrations 
of BU09057 (A, B), BU09058 (C, D), and BU09059 (E, F). Apart from BU09059, all ligands 
tested caused rightward parallel shifts in the concentration response curves of both U50,488 
and DAMGO. Results are expressed as the mean percentage of the maximum response induced 
by the agonist ± SEM, , n=4 tissues. 
 
Figure 3. Cumulative concentration-response curves, in the mouse vas deferens, for DAMGO 
(maximal agonist concentration 2 M) (A) and DPDPE (maximal agonist concentration 20 
nM),  (B), in the presence of high concentrations of BU09059. Results are expressed as the 
mean percentage of the maximum response induced by the agonist ± SEM, , n=4 tissues. 
 
Figure 4. Ability of the test compounds BU09057, BU09058 and BU09059 to block  U50,488-
induced antinociception in the tail-withdrawal test. Mice received a single injection of 0.9% 
(w/v) saline, BU09057 (A), BU09058 (B) BU09059 (C) and norBNI (D) at both 3 mg/kg (□) 
and 10 mg/kg (■) and tail-withdrawal latency measured at intervals up to 21 days post injection. 
U50,488 (10mg/kg) was injected on each test occasion, 30 min prior to measuring tail-
withdrawal latency. Data are expressed as mean percentage maximum possible effect (%MPE) 
± SEM, n=8 per treatment group.   
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FIGURE 1 
   
 
 BU09057 BU09058 BU09059 JDTic 
TPSA 82.03 82.03 111.13 84.8 
H-bond donors 3 3 4 4 
H-bond acceptors 6 6 8 6 
Rotatable bonds 6 7 8 6 
logP 2.70 2.90 2.02 2.93 
M.Wt 424 438 495 465 
Predicted to be 
CNS active 
Yes Yes Yes Yes 
 
 32
FIGURE 2 
 
 33
FIGURE 3 
 
 34
FIGURE 4 
 
 
 35
Graphic for table of contents 
 
 
 
 
 
